



Monitoring target reduction in hepatic venous pressure gradient during pharmacological therapy of portal hypertension: a close look at the evidence

U Thalheimer, M Mela, D Patch and A K Burroughs

Gut 2004;53:143-148
doi:10.1136/gut.53.1.143

Updated information and services can be found at:
<http://gut.bmjournals.com/cgi/content/full/53/1/143>

These include:

References

This article cites 50 articles, 5 of which can be accessed free at:
<http://gut.bmjournals.com/cgi/content/full/53/1/143#BIBL>

1 online articles that cite this article can be accessed at:
<http://gut.bmjournals.com/cgi/content/full/53/1/143#otherarticles>

Rapid responses

2 rapid responses have been posted to this article, which you can access for free at:
<http://gut.bmjournals.com/cgi/content/full/53/1/143#responses>

You can respond to this article at:
<http://gut.bmjournals.com/cgi/eletter-submit/53/1/143>

Email alerting service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

Topic collections

Articles on similar topics can be found in the following collections

[Drugs: gastrointestinal system](#) (430 articles)
[Hypertension](#) (418 articles)
[Liver, including hepatitis](#) (844 articles)

Notes

To order reprints of this article go to:
<http://www.bmjournals.com/cgi/reprintform>

To subscribe to *Gut* go to:
<http://www.bmjournals.com/subscriptions/>

OCCASIONAL VIEWPOINT

Monitoring target reduction in hepatic venous pressure gradient during pharmacological therapy of portal hypertension: a close look at the evidence

U Thalheimer, M Mela, D Patch, A K Burroughs

Gut 2004;53:143–148

Recurrent variceal bleeding is very frequent after variceal haemorrhage and pharmacological therapy is the first choice treatment. Recently, baseline and repeat measurements of hepatic venous pressure gradient (HVPG) have been considered necessary to optimally manage patients receiving pharmacological therapy so as to reduce the frequency of rebleeding. However, the clinical validity and applicability of monitoring for target HVPG reductions is not sufficiently proven and needs to be specifically evaluated in a prospective trial.

sclerotherapy^{1,2} and banding for both primary³ and secondary prophylaxis.^{4–6} In early studies^{1–3} non-selective beta blockade dosage was empirical (that is, to the maximum tolerated by the patient or to reduction of the resting pulse rate to 55/min). However, the key issue is whether targeted reduction of portal pressure, which involves a baseline and a repeated hepatic venous pressure gradient measurement (HVPG), is necessary in routine clinical practice. It significantly adds to the cost of pharmacological therapy, it is not universally available, and several issues regarding its use are as yet not clear,⁷ despite it being recommended in two recent reviews.^{8,9} Moreover, the cost effectiveness of HVPG measurement has been questioned in primary prevention¹⁰ and, furthermore, HVPG is known to decrease with time even in some untreated patients.^{11,12} Despite a recent paper on tailoring of drug therapy,¹³ only some of the above issues have been considered.^{7,14}

SUMMARY

Recurrent variceal bleeding is very frequent after variceal haemorrhage unless secondary prevention with pharmacological or endoscopic therapy is used. Recently, baseline and repeat measurements of hepatic venous pressure gradient (HVPG) have been considered necessary to optimally manage patients receiving pharmacological therapy so as to reduce the frequency of rebleeding, by defining two targets: $\geq 20\%$ reduction from baseline HVPG, and an absolute reduction to ≤ 12 mm Hg. Five key studies are identified which contain data related to this issue, which are different in their study populations as regards number of patients, proportion of alcoholics, and those with severe liver disease. Importantly, 17–65% of patients did not have a baseline and/or a repeat HVPG measurement, many because they rebled early (7–22%), limiting the clinical applicability of HVPG measurement. These groups are excluded from evaluation in those studies where the relationship between reduction of rebleeding and haemodynamic targets is strongest. This important source of bias, as well as other contrasting data, make it difficult to interpret the prognostic significance of haemodynamic data and to propose their routine clinical use. In conclusion, the clinical validity and applicability of monitoring for target HVPG reductions is not sufficiently proven by these studies and needs to be specifically evaluated in a prospective trial.

INTRODUCTION

Pharmacological therapy is the first choice treatment for the prevention of variceal rebleeding as it is equivalent but less costly than

THE KEY STUDIES

There have been five major studies^{4,6,15–17} and one smaller series published as a correspondence¹⁸ in the context of prevention of variceal rebleeding in which HVPG has been measured at baseline and at a subsequent time point (table 1). Their targeted end points were all the same following the first report.¹⁵ These were an absolute reduction in HVPG to 12 mm Hg or less, or a 20% reduction or more in HVPG from baseline, and the occurrence of rebleeding from varices.

The main data of these five studies are summarised in tables 1–3, with additional data from our own study.⁶

The study by Sacerdoti and colleagues¹⁸ included only 11 cirrhotic patients treated with nadolol. Haemodynamic response, defined as a decrease in HVPG of only $\geq 12\%$, was observed in 54% of patients at one month, of whom none rebled. Among non-responders, 80% had rebleeding, the same proportion as in 11 untreated cirrhotic patients who served as controls.

SIMILARITIES AND DIFFERENCES BETWEEN THE KEY STUDIES

Superficially all of these studies appear similar but there are some marked differences between them, making the haemodynamic data difficult

See end of article for authors' affiliations

Correspondence to: Professor A K Burroughs, Hepatobiliary Medicine and Liver Transplant Unit, Royal Free Hospital, Pond St, London NW3 2QG, UK; Andrew.Burroughs@royalfree.nhs.uk

Accepted for publication 22 August 2003

Abbreviations: HVPG, hepatic venous pressure gradient

Table 1 Key published studies of repeated hepatic venous pressure gradient (HVPG) measurement in the prevention of variceal rebleeding: total populations and haemodynamic responders (absolute numbers of patients in parentheses)

	Feu ¹⁵	Villanueva ¹⁶	McCormick ¹⁷	Villanueva ⁴	Patch ⁶
Total No of patients	83	43*	63	72†	51‡
% of patients with baseline HVPG measured	83% (69)	100% (43)	89% (56)	100% (72)	78% (40)
% of patients with remeasurement of HVPG	83% (69)	72% (31)	71% (45)§	68% (49)	35% (18)
Time of, or mean interval to, remeasurement (months)	3	3–4	5.3	1–3	2
Child class C	6% (4)	16% (7)	6% (4)	19% (14)	47% (24)
Alcoholic aetiology	59% (41)	51% (25)	70% (31)	50% (43)	63% (32)
Follow up (months) (median [range])	28 [1–69]**	18 [4–36]	22** responders, 26** non-responders [0.1–60]	20 [1–65]	8 [0.25–46]
Patients with nitrates	0	100% (43)	68% (30)	100% (72)	41% (22)
Baseline HVPG (mm Hg) (mean (SD))	18.3 (3.6)	17.7 (3.4)	17.5 (0.6) responders 18 (1.0) non responders	19.9 (3.5)	18.3 (4.9)
Haemodynamic responders	36% (25)	45% (14)	64% (28)	51% (25)	50% (9)
Rebleeding in patients with baseline HVPG measurement	36% (25)	26% (11)	37% (16)¶	33% (24)	37% (19)
Mortality in patients with baseline HVPG measurement	13% (9)	9% (4)	n/a	32% (23)	33% (17)

*Initial cohort 121 patients, 86 of whom were included (43 for each treatment arm).

†Initial cohort 233 patients, 144 of whom were included (72 for each treatment arm).

‡Initial cohort 205 patients, 102 of whom were included (51 for each treatment arm).

§Only 44 patients included in the study (one patient excluded because of low initial and repeat HVPG (7 mm Hg)).

¶Calculated on the 44 included patients.

**Mean [range].

to interpret, and raising questions as to their use as valid therapeutic targets for pressure reduction (tables 1, 2).

Patients in whom no baseline HVPG measurement or remeasurement took place (table 2)

Not all patients had HVPG measured and/or remeasured, and therefore in this subgroup responder/non-responder status could not be assessed, varying from 65% in the study of Patch and colleagues⁶ to 17% in that of Feu and colleagues.¹⁵ Importantly, the rebleeding rate among these patients varied from 17%^{4,16} to 64%.¹⁵ However, the situation is more complex than one would expect. In Feu's study¹⁵ the rebleeding rate was higher than in the non-responder group, as was the case in Patch's study,⁶ while in McCormick's study¹⁷ it was approximately equivalent to the non-responder group. In the studies of Villanueva and colleagues,^{4,16} the rebleeding rate in patients in whom no repeat HVPG measurement took place was the same in both studies, being intermediate between the rebleeding rate in responders and

non-responders in the first study¹⁶—the expected outcome—but in the second study it was equivalent to the responders' rebleeding rates.⁴ This represents an important source of bias.

Interval to remeasurement of HVPG

One reason why remeasurement could not take place is that some patients rebled before the second haemodynamic measurement: "some" (that is, no number specified) in the Villanueva papers,^{4,16} 7% in Feu and colleagues,¹⁵ 16% in McCormick and colleagues,¹⁷ and 22% in Patch and colleagues.⁶

"Clearly, if many patients rebleed very early, it greatly diminishes the clinical applicability of remeasuring HVPG"

This raises an issue of when to remeasure HVPG,¹⁴ as the intervals to remeasurement (table 1) were 1–3 months,⁴ 3 months,^{15,16} a mean of 5.3 months,¹⁷ and a mean of 57 days.⁶ Overall, between 25% and 44% of rebleeders rebled

Table 2 Patients rebleeding in the key study populations of repeated hepatic venous pressure gradient (HVPG) measurement in the pharmacological prevention of variceal rebleeding (absolute numbers in parentheses)

	Feu ¹⁵	Villanueva ¹⁶	McCormick ¹⁷	Villanueva ⁴	Patch ⁶
Total No of patients	83	43*	63	72†	51‡
HVPG not measured	17% (14)	0%	11% (7)	0%	22% (11)
HVPG not remeasured	17% (14)	28% (12)	17% (11)§	33% (23)	65% (33)
Rebleeding not remeasured	64% (9/14)	17% (2/12)	28% (5/18)¶	17% (4/23)	33% (11/33)
Rebleeding (patient groups)					
Total	36% (25/69)	26% (11/43)	37% (16/44)	33% (24/72)	37% (19/51)
Haemodynamic responders	8% (2/25)	7% (1/14)	43% (12/28)	16% (4/25)	11% (1/9)
Haemodynamic non-responders	52% (23/44)	47% (8/17)	25% (4/16)	67% (16/24)	22% (2/9)
Repeat HVPG ≤ 12 mm Hg	0% (0/8)	0% (0/9)	30% (7/23)	? (?/7)	50% (1/2)
Rebleeding before remeasurement	7% (5/69)	Some**	16% (7/44)	Some**	22% (5/23)

*Initial cohort 121 patients, 86 of whom were included (43 for each treatment arm).

†Initial cohort 233 patients, 144 of whom were included (72 for each treatment arm).

‡Initial cohort 205 patients, 102 of whom were included (51 for each treatment arm).

§Only 44 patients included in the study (one patient excluded because of low initial and repeat HVPG (7 mm Hg)).

¶Rebleeding rate in both non-measured and non-remeasured patients (rebleeding occurred in two of seven patients who did not have their baseline HVPG measured and in three of 11 patients who did not have a repeat HVPG measurement).

**Number not stated (in the second study (Villanueva⁴) it can be derived that this number must be between 1 and 4).

Table 3 Independent risk factors for variceal rebleeding in the key studies

Feu ¹⁵	Absence of haemodynamic response
Villanueva ¹⁶	Sclerotherapy v drug treatment HVPG at 3rd month
Villanueva ⁴	Endoscopic banding ligation v drug treatment Absence of haemodynamic response Child-Pugh score at 3rd month
Patch ⁶	HVPG at baseline

HVPG, hepatic venous pressure gradient.

before remeasurement. Clearly, if many patients rebleed very early, it greatly diminishes the clinical applicability of remeasuring HVPG.

The proportion of haemodynamic responders in the drug arms of all studies varied between 36%¹⁵ and 64%.¹⁷ This variability could be influenced, and thus explained, by the time interval to the second HVPG measurement. The variability is not explained by the proportion of Child class C patients, although many may have rebled early, or by the baseline HVPG value or by mean drug dosage.

The lowest haemodynamic response rate was found by Feu and colleagues,¹⁵ perhaps because their patients did not receive nitrates. In McCormick's study,¹⁷ which had the highest haemodynamic response rate, 68% of patients had nitrates added (although the mean nitrate dose was about half that used in the Villanueva studies^{4, 16}), yet there was also the longest time interval to remeasurement.

Rates of rebleeding

The overall rebleeding rates in those patients in whom HVPG was remeasured were very similar in the four studies, varying between 33% and 37%, with the exception of the first Villanueva study¹⁶ which also used nitrates in which the rebleeding rate was 26%. These data are consistent with the second study,⁴ which also used nitrates, because if one excludes the 12 patients who did not receive nadolol throughout (eight of them subsequently rebled) the rebleeding rate was 27%. These lower rebleeding rates may be related to the shorter follow up in these two studies rather than to the use of nitrates because the other studies which also used nitrates^{6, 17} had higher rebleeding rates similar to that of Feu and colleagues¹⁵ in which only propranolol was used.

There was a higher rebleeding rate in cohorts with a higher proportion of alcoholic cirrhotics: from 26% in the first Villanueva study,¹⁶ which had the equal lowest percentage (51%) of patients with alcoholic liver disease, to 37% in McCormick *et al*'s study¹⁷ whose cohort has a 70% prevalence; if compliant with therapy and a target of 12 mm Hg or less was reached, there was a low rebleeding rate (9%).

Relationship between rebleeding and haemodynamic response rate

A cardinal point in comparing these studies is that no clear correlation exists between the haemodynamic response rate and rebleeding. Indeed, the study with the highest haemodynamic response rate¹⁷ had the equal highest rebleeding rate (37%), even though the percentage of patients in Child class C was only 6%. Moreover, in the study of Feu and colleagues¹⁵ the rebleeding rate was similar to most of the other studies despite the lowest haemodynamic response rate and the longest follow up.

“No clear correlation exists between the haemodynamic response rate and rebleeding”

The rebleeding rate in haemodynamic responders varied widely between 7% and 43%, and the rebleeding rate in

non-responders between 22% and 67%. This was mainly due to the study by McCormick and colleagues¹⁷ which reported a 43% rebleeding rate in responders and a 25% rebleeding rate in non-responders. Excluding the study by McCormick and colleagues,¹⁷ the rebleeding rate in haemodynamic responders varied from 7% to 16%.

In the responder group, there was a trend for a lower rebleeding rate the earlier the response of HVPG was assessed (with a concurrent higher rebleeding rate in non-responders), especially if the small study by Sacerdoti and colleagues¹⁸ with HVPG remeasurement at one month is considered. This could be due to the importance of an early decrease in HVPG as recurrent bleeding seems to be more frequent in the first weeks after the index bleed and HVPG tends to decrease with time, as mentioned previously.¹¹ This would concur with the lack of correlation between responder status and rebleeding in the study by McCormick and colleagues¹⁷ in which HVPG was remeasured at a mean of over five months. Conversely, there was a low incidence of recurrent bleeding in the non-responder group in the study of Patch and colleagues⁶ (22%) despite a median time of only 49 days to the second HVPG remeasurement. This could be due to the bias of exclusion of those patients who rebled before remeasurement.

There were lower rebleeding rates in non-responders in the studies with a higher percentage of alcoholic cirrhotics so that the relationship between responder status and rebleeding risk may be different in alcoholic cirrhotics compared with others. Abstinence may have a major influence on haemodynamic response and rebleeding rates,¹² and conversely non-compliance may lead to more rebleeding. This may also explain the lack of relationship between haemodynamic response and rebleeding rates in McCormick's study¹⁷ (with the highest prevalence of alcoholic cirrhosis). These issues have not been adequately assessed in all of the studies.

Influence of baseline HVPG

Interpretation of the prognostic value of baseline HVPG could be affected by excluding patients who rebled before remeasurement. This was not the case in the study by Patch and colleagues⁶ in which several patients who rebled did so before remeasurement but were not excluded from the evaluation of baseline HVPG. Indeed, only in this study was baseline HVPG reported to be predictive of rebleeding while the other studies did not specifically comment on this.

An interesting comparison can be made in the two papers by Villanueva and colleagues^{4, 16} which were very similar with regard to the population studied, treatment given, schedule of haemodynamic measurements, and duration of follow up (table 1). The main difference between the studies was baseline HVPG, which was substantially higher in the second study (mean HVPG 19.9 (3.5) v 17.7 (3.4) mm Hg). This probably explains the higher mortality (32% v 9%) in this study. Indeed, there is an increase in mortality with increasing HVPG in many studies in hepatology,¹⁹ including a study in which HVPG was measured at two days after bleeding.²⁰ The higher mean baseline HVPG could also be an explanation for drug treatment only reducing rebleeding rates in Child A patients in the second Villanueva study⁴ while rebleeding rates were similar in all Child classes in the first study.¹⁶ In this first study, Child B and Child C patients could have benefited because their baseline HVPG was already lower. Moreover, in the second Villanueva study,⁴ six patients randomised did not start nadolol therapy because of contraindications and were only given isosorbide mononitrate, and another six patients stopped nadolol (two due to complications and four due to non-compliance). Of these 12 patients, eight rebled, which means that at least two and perhaps all six patients who had contraindications to nadolol

rebled. Clearly, an intention to treat analysis is correct statistically but in the clinical interpretation of rebleeding, patients who had contraindications to nadolol, and therefore never had the drug administered, cannot be considered failures of drug therapy. Because it was not stated whether the six patients who suspended nadolol did or did not have a second haemodynamic measurement, it is again difficult to interpret the relationship between rebleeding and haemodynamic measurement.

OTHER STUDIES

In some of these, the definition of haemodynamic response was not defined²¹ or the percentage of haemodynamic responders and non-responders was not reported,²² and thus cannot be evaluated.

“Early measurement of HVPG after bleeding within 48 hours correlates with early rebleeding”

Early measurement of HVPG after bleeding within 48 hours correlates with early rebleeding.²³ The prognostic value of a single HVPG measurement in patients with recent bleeding with respect to rebleeding has been assessed in five studies^{6 20 24–26}; three^{20 24 25} failed to show a correlation between HVPG and rebleeding in contrast with the other two.^{6 26} Differences in timing of HVPG measurement make it difficult to compare these studies directly, again underscoring the need for standardisation before the prognostic value of this technique can be considered valid.

The acute HVPG response to a single oral dose of propranolol did not predict rebleeding in 77 patients.²⁴ A study²⁷ of a single intravenous dose of propranolol (33 patients) did not report rebleeding in non-responders so that it is impossible to assess.

Two other studies^{13 28} have also considered the importance of haemodynamic monitoring for preventing variceal bleeding during drug therapy, but their study populations comprised combined groups with and without a history of prior variceal haemorrhage, and thus cannot be readily compared with the key studies discussed above. Indeed, there seems to be a difference in haemodynamic response in patients receiving pharmacological therapy for primary compared with secondary prevention of variceal bleeding,^{13 27} as well as very different risks of bleeding. In patients without varices, HVPG reduction after beta blockade is greater than that in those with varices.²⁹ Populations of primary and secondary prevention should be kept apart when evaluating study results.

“There seems to be a difference in haemodynamic response in patients receiving pharmacological therapy for primary compared with secondary prevention of variceal bleeding”

A recent study³⁰ found that a lack of haemodynamic response during drug therapy for secondary prevention of variceal bleeding was associated not only with rebleeding but also with development of ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, and hepatic encephalopathy, as well as with a tendency to reduced survival, but it is unclear if there was a concomitant improvement in liver function.

Fewer data exist for monitoring target reduction of HVPG in primary prophylaxis.^{11 31} Merkel and colleagues³¹ found that variceal bleeding was significantly more likely in poor responders while there was no significant difference in baseline HVPG between bleeders and non-bleeders; none of the patients with a HVPG ≤ 12 mm Hg suffered a haemorrhage.

Groszmann and colleagues¹¹ found that no patient who achieved a HVPG of ≤ 12 mm Hg during subsequent measurements experienced a haemorrhage. When propranolol was withdrawn, the risk of variceal haemorrhage returned to what would be expected in an untreated population so that lifelong therapy is needed.³²

PRECISION OF HVPG MEASUREMENT

A recent report comprising 102 patients³³ suggested that HVPG measurement itself may not be as reliable as previously thought^{34–41} as 61% had a difference of between 4 and 34 mm Hg in HVPG measurement in two separate hepatic veins. If a 4 mm Hg difference in HVPG is considered, when baseline HVPG is 20 mm Hg, this already produces a 20% change. Thus defining a haemodynamic response by a percentage HVPG decrease of this magnitude, such as in this example, could be flawed due to the variability in measurement. However, in practice, the same hepatic vein is usually cannulated but nevertheless even when considering an intra-subject variation of 1–2 mm Hg, which is commonly acknowledged,¹⁹ this can make a difference in considering whether a patient is above or below 12 mm Hg or achieves a decrease of more or less than 20% from baseline. It is self evident that it is much easier to achieve a 20% decrease, with a lower HVPG baseline value; the lower rebleeding rate in patients with a $\geq 20\%$ decrease may indeed be correlated with a lower baseline HVPG value, as was the case in two of the studies.^{6 26}

DISCUSSION

Detailed evaluation of the key studies showed great heterogeneity in the data. In particular, the patient populations were different in the proportion of alcoholic patients and those with severe liver disease. Baseline HVPG and the interval to remeasurement were also very variable, which obviously can lead to different proportions of patients achieving the target reductions of $\geq 20\%$ reduction in HVPG from baseline and ≤ 12 mm Hg absolute reduction. In addition, there is a spontaneous reduction in HVPG with time,^{11 12} particularly in alcoholics¹² who abstain.⁴² Lastly, the use of combination therapy, particularly nitrates, and perhaps spironolactone (not detailed in all studies, although ascitic patients are included), could affect the proportion of responders and rebleeders.^{43–46} The error in measurement³³ may come into play, particularly if patients with lower pressures are being considered.

“We view the current data as insufficient evidence to support monitoring the targeted reduction of HVPG in routine clinical practice”

Therefore, the haemodynamic targets themselves, whether or not achieved by combination therapy or whenever achieved in time from the index bleeding episode, cannot be considered robust and clinically applicable. We view the current data as insufficient evidence to support monitoring the targeted reduction of HVPG in routine clinical practice, as is now recommended.^{8 9}

Firstly, the bias introduced due to rebleeding before remeasurement of HVPG in some patients and failure to remeasure HVPG in all patients makes it very difficult to be certain of the haemodynamic thresholds.

The interval to remeasurement is of undeniable importance.^{9 47} The known reduction of HVPG with time after variceal bleeding makes it difficult to compare studies. Failure to achieve the haemodynamic target without rebleeding may be very relevant clinically. If after a long period the patient has not rebled, despite not achieving the haemodynamic targets, this may mean that for this particular patient

the likelihood of rebleeding is far less. This needs to be studied.

It is possible that for the predictive assessment of pressure measurement in response to medical treatment for the prevention of variceal rebleeding, the baseline HVPG value could be of even greater importance than the haemodynamic response. The decrease in HVPG by $\geq 20\%$ or to ≤ 12 mm Hg may be an expression of a lower baseline HVPG value. This could be especially true if those patients who rebleed early, and thus cannot have a remeasurement, have a higher baseline HVPG.

Combination therapy with nitrates increases the percentage of haemodynamic responders,⁴⁸ as assessed by HVPG, but its increased therapeutic efficacy compared with a non-selective beta blocker on its own in randomised clinical trials for preventing rebleeding is not established, with two studies coming to opposite conclusions.^{49, 50}

Do haemodynamic targets have prognostic value? There is little doubt that if one considers cohorts of patients, HVPG is indeed correlated with the risk of variceal bleeding, and that theoretically, target reduction could be of some use in evaluating the response during drug therapy. However, the evidence for the 20% HVPG decrease from baseline as an appropriate target reduction seems to be of questionable value due to the biases illustrated in the studies. In contrast, decrease in HVPG to a value of 12 mm Hg does seem to be of prognostic significance in the majority of studies, but as it only identifies a small percentage of patients (12–48%, median 14%)^{4, 6, 15–17} it makes HVPG measurement and remeasurement of little clinical applicability.

“Logically, one should use target reduction in HVPG as a means of identifying patients who are less likely to bleed while complying with their given therapy”

Logically, one should use target reduction in HVPG as a means of identifying patients who are less likely to bleed while complying with their given therapy, and for those who do not achieve these targets, to offer them alternative therapy that will reduce their risk of rebleeding and improve survival. Ultimately, the only means of assessing the clinical utility of evaluating the haemodynamic response in patients given drug therapy for secondary prophylaxis of variceal bleeding would be a trial in which there would be four groups: one without HVPG measurement, and the other three groups in which HVPG measurements were performed. These three groups would be identified by randomisation at the second HVPG measurement so that haemodynamic non-responders would be randomised, either to continuation of drug therapy or to an alternative treatment such as endoscopic banding ligation with or without drugs. The remaining group would be the haemodynamic responders. In such a study an appropriate time interval which is clinically applicable for the repeat measurement would need to be defined a priori, perhaps as short as two weeks from the index bleeding episode.

Authors' affiliations

U Thalheimer, M Mela, D Patch, A K Burroughs, Liver Transplantation and Hepatobiliary Unit, Royal Free Hospital, Pond St, London NW3 2QG, UK

REFERENCES

- 1 D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. *Hepatology* 1995;**22**:332–54.
- 2 DeFranchis R, Primignani M. Endoscopic treatment for portal hypertension. *Semin Liver Dis* 1999;**19**:439–55.

- 3 Imperiale TF, Chalasani N. A meta-analysis of endoscopic variceal ligation for primary prophylaxis of esophageal bleeding. *Hepatology* 2000;**33**:1003–4.
- 4 Villanueva C, Minana J, Ortiz J, et al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. *N Engl J Med* 2001;**345**:647–55.
- 5 Lo G-H, Chen W-C, Chen M-H, et al. Banding ligation versus nadolol and isosorbide mononitrate for the prevention of esophageal variceal rebleeding. *Gastroenterology* 2002;**123**:728–34.
- 6 Patch D, Sabin CA, Gouliis J, et al. A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. *Gastroenterology* 2002;**123**:1013–19.
- 7 Bosch J. A la carte or menu fixe: improving pharmacologic therapy of portal hypertension. *Hepatology* 2002;**36**:1330–2.
- 8 Bosch J, Abraldes JG, Groszmann R. Current management of portal hypertension. *J Hepatol* 2003;**38**(suppl 1):S54–68.
- 9 Bosch J, Garcia-Pagan JC. Prevention of variceal bleeding. *Lancet* 2003;**361**:952–4.
- 10 Hicken BL, Sharara AI, Abrams GA, et al. Hepatic venous pressure gradient measurements to assess response to primary prophylaxis in patients with cirrhosis: a decision analytical study. *Aliment Pharmacol Ther* 2003;**17**:145–53.
- 11 Groszmann RJ, Bosch J, Grace ND, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. *Gastroenterology* 1990;**99**:1401–7.
- 12 Vorobioff J, Groszmann RJ, Pibacea E, et al. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. *Gastroenterology* 1996;**111**:701–9.
- 13 Bureau C, Péron JM, Alric L, et al. “A la carte” treatment of portal hypertension: adapting medical therapy to hemodynamic response for the prevention of bleeding. *Hepatology* 2002;**36**:1361–6.
- 14 Groszmann RJ, Garcia-Tsao G. Endoscopic variceal banding vs. pharmacological therapy for the prevention of recurrent variceal haemorrhage: what makes the difference. *Gastroenterology* 2002;**123**:1388–91.
- 15 Feu F, Garcia-Pagan JC, Bosch J, et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. *Lancet* 1995;**346**:1056–9.
- 16 Villanueva C, Balanzo J, Novella MT, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. *N Engl J Med* 1996;**334**:1624–9.
- 17 McCormick PA, Patch D, Greenslade L, et al. Clinical vs hemodynamic response to drugs in portal hypertension. *J Hepatol* 1998;**28**:1015–19.
- 18 Sacerdoti D, Merkel C, Gatta A. Importance of the 1-month-effect of nadolol on portal pressure in predicting failure of prevention of rebleeding in cirrhosis. *J Hepatol* 1991;**12**:124–5.
- 19 Armonis A, Patch D, Burroughs AK. Hepatic venous pressure measurement: an old test as a new prognostic marker in cirrhosis? *Hepatology* 1997;**25**:245–8.
- 20 Vinel JP, Cassigneul J, Levade M, et al. Assessment of short-term prognosis after variceal bleeding in patients with alcoholic cirrhosis by early measurement of portohepatic gradient. *Hepatology* 1986;**6**:116–17.
- 21 Burroughs AK, Jenkins WJ, Sherlock S, et al. Controlled trial of propranolol for the prevention of recurrent variceal hemorrhage in patients with cirrhosis. *N Engl J Med* 1983;**309**:1539–42.
- 22 Escorsell A, Bañares R, Garcia-Pagan JC, et al. TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: a randomized controlled trial. *Hepatology* 2002;**35**:385–92.
- 23 Moitinho E, Escorsell A, Bandi JC, et al. Prognostic value of early measurements of portal pressure in acute variceal bleeding. *Gastroenterology* 1999;**117**:626–31.
- 24 Valla D, Jiron MI, Poynard T, et al. Failure of haemodynamic measurements to predict recurrent gastrointestinal bleeding in cirrhotic patients receiving propranolol. *J Hepatol* 1987;**5**:144–8.
- 25 Patch D, Armonis A, Sabin K, et al. Single portal pressure measurement predicts survival in cirrhotic patients with recent bleeding. *Gut* 1999;**44**:264–9.
- 26 Vlavianos P, Gimson ES, Hayllar K, et al. Prognostic significance of systemic and portal haemodynamic parameters in patients with cirrhosis and previous variceal bleeding. *Gut* 1990;**31**:592A.
- 27 De BK, Sen S, Biswas PK, et al. Propranolol in primary and secondary prophylaxis of variceal bleeding among cirrhotics in India: a hemodynamic evaluation. *Am J Gastroenterol* 2000;**95**:2023–8.
- 28 Escorsell A, Bordas JM, Castañeda B, et al. Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension. *Hepatology* 2000;**31**:1061–7.
- 29 Escorsell A, Ferayorni L, Bosch J, et al. The portal pressure response to β -blockade is greater in cirrhotic patients without varices than in those with varices. *Gastroenterology* 1997;**112**:2012–16.
- 30 Abraldes JG, Tarantino I, Turnes J, et al. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. *Hepatology* 2003;**37**:902–8.
- 31 Merkel C, Bolognesi M, Sacerdoti D, et al. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. *Hepatology* 2000;**32**:930–4.
- 32 Abraczinskas DR, Ookubo R, Grace ND, et al. Propranolol for the prevention of first esophageal variceal hemorrhage: a lifetime commitment? *Hepatology* 2001;**34**:1096–102.
- 33 Keiding S, Vilstrup H. Intrahepatic heterogeneity of hepatic venous pressure gradient in human cirrhosis. *Scand J Gastroenterol* 2002;**37**:960–4.

- 34 **Rector WG**. Propranolol for portal hypertension. Evaluation of therapeutic response by direct measurement of portal vein pressure. *Arch Intern Med* 1985;**145**:648–50.
- 35 **Viallet A**, Joly JG, Marleau D, et al. Comparison of free portal venous pressure and wedged hepatic venous pressure in patients with cirrhosis of the liver. *Gastroenterology* 1970;**59**:372–5.
- 36 **Iwao T**, Toyonaga A, Ikegami M, et al. Wedged hepatic venous pressure reflects portal venous pressure during vasoactive drug administration in non-alcoholic cirrhosis. *Dig Dis Sci* 1994;**39**:2439–44.
- 37 **Perelló A**, Escorsell A, Bru C, et al. Wedged hepatic venous pressure adequately reflects portal pressure in hepatitis C virus-related cirrhosis. *Hepatology* 1999;**30**:1393–7.
- 38 **Boyer TD**, Triger DR, Horisawa M, et al. Direct transhepatic measurement of portal vein pressure using a thin needle. Comparison with wedged hepatic vein pressure. *Gastroenterology* 1977;**72**:584–9.
- 39 **Groszmann RJ**, Glickman M, Blei AT, et al. Wedged and free hepatic venous pressure measured with a balloon catheter. *Gastroenterology* 1979;**76**:253–8.
- 40 **Lin HC**, Tsai YT, Lee FY, et al. Comparison between portal vein pressure and wedged hepatic vein pressure in hepatitis B-related cirrhosis. *J Hepatol* 1989;**9**:326–30.
- 41 **Reynolds TB**, Ito S, Iwatsuki S. Measurement of portal pressure and its clinical application. *Am J Med* 1970;**49**:649–57.
- 42 **Reynolds TB**, Geller HM, Kuzma OT, et al. Spontaneous decrease in portal pressure with clinical improvement in cirrhosis. *N Engl J Med* 1960;**263**:734–9.
- 43 **Okumura H**, Arakami T, Katsuta Y, et al. Reduction in hepatic venous pressure gradient as a consequence of volume contraction due to chronic administration of spironolactone in patients with cirrhosis and no ascites. *Am J Gastroenterol* 1991;**86**:46–52.
- 44 **García-Pagán J**, Salmeron J, Feu F, et al. Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis. *Hepatology* 1994;**19**:1095–9.
- 45 **Sugano S**, Kawafune T, Okajima T, et al. Chronic splanchnic hemodynamic effects of spironolactone with unrestricted sodium diet in patients with compensated cirrhosis. *Dig Dis Sci* 1998;**43**:893–7.
- 46 **Nevens F**, Lijnen P, VanBilloen H, et al. The effect of long-term treatment with spironolactone on variceal pressure in patients with portal hypertension without ascites. *Hepatology* 1996;**23**:1047–52.
- 47 **Thalheimer U**, Mela M, Patch D, et al. Prevention of variceal rebleeding. *Lancet* 2003;**361**:2244–5.
- 48 **García-Pagán JC**, Feu F, Bosch J, et al. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study. *Ann Intern Med* 1991;**114**:869–73.
- 49 **Gournay J**, Masliah C, Martin T, et al. Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding. *Hepatology* 2000;**31**:1239–45.
- 50 **Patti R**, D'Amico G, Pasta L, et al. Isosorbide mononitrate (IMN) with nadolol compared to nadolol alone for prevention of recurrent bleeding in cirrhosis. A double-blind placebo-controlled randomised trial. *J Hepatol* 1999;**30**(suppl 1):81A.

Gut through the ages

[Browse the Archive](#)

Gut online has an archive of content dating back to 1966.
Full text from 1997; abstracts from 1975; table of contents from 1966

www.gutjnl.com